Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 4/20 | 0.39 |
| ▸ | REN | P00797 | 2/20 | 0.36 |
| ▸ | AKT1 | P31749 | 4/20 | 0.36 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.35 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1097046 | 0.94 | CCR5 (0.37) | CCR5RENAKT1RPS6KB1SSTR4 | |
| SCHEMBL1096262 | 0.92 | REN (0.37) | RENSSTR4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3576110 | 0.88 | CCR5 (0.38) | CCR5AKT1RPS6KB1SSTR4SLC6A2 | |
| SCHEMBL1096491 | 0.87 | REN (0.36) | RENSSTR4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1095799 | 0.85 | MAPT (0.38) | RENSSTR4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL16274994 | 0.84 | REN (0.40) | RENSSTR4 | |
| SCHEMBL1095976 | 0.82 | CCR5 (0.39) | CCR5AKT1RPS6KB1 | |
| SCHEMBL1095954 | 0.82 | SSTR4 (0.35) | RENSSTR4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3570815 | 0.81 | RPS6KB1 (0.38) | CCR5AKT1RPS6KB1SSTR4SLC6A2 | |
| SCHEMBL1105750 | 0.81 | CCR5 (0.40) | CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153658-B2 | Piperidine derivative or salt thereof | ASTELLAS PHARMA, INC. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-8153658-B2 | Piperidine derivative or salt thereof | ASTELLAS PHARMA, INC. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-8153658-B2 | Piperidine derivative or salt thereof | ASTELLAS PHARMA, INC. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | CASR, CYP2R1, HCAR1 | CCR5 542/4885REN 20/4885AKT1 3021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.